Lumata Health Secures $23 Million Series B Funding

Lumata Health announced that it has raised $23 million in Series B funding, bringing its total raised since inception to $36 million. Lumata said the investment will enable the company to meet growing demand and further enhance the data-driven technology powering its patient adherence solutions.

Lumata Health’s platform aims to address systemic barriers that delay or prevent timely care for patients with sight-threatening conditions. It does this by combining predictive analytics with personalized interventions—recently demonstrating that up to 800 additional vision-saving eye injections are delivered annually for every 1,000 participating patients. This proactive model not only preserves sight but also significantly reduces long-term healthcare costs associated with vision loss, according to Lumata Health. 

The round was co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from existing investors including Cortado Ventures.

“We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases,” Landon Grace, CEO of Lumata Health, said in a company news release. “This investment will allow us to continue scaling our data-driven approach to ensuring access and adherence to vision-saving treatments for the millions of people in the US with these conditions.”

Over the past 3 years, Lumata said it has partnered with eye care providers across the country, including the five largest national and regional eye care networks. 

“With millions of Americans at risk of preventable blindness, we’re investing in Lumata Health because it is uniquely positioned to drive meaningful change at scale,” said Ellen Herlacher, Partner at LRVHealth. “By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.”